{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:17:37Z","timestamp":1722212257419},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,28]]},"DOI":"10.7759\/cureus.65591","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T18:35:50Z","timestamp":1722191750000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk"],"prefix":"10.7759","author":[{"given":"Knkush","family":"Hakobyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talar","family":"Acob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesrop","family":"Aleksanyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigran","family":"Kakhktsyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Jumaah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajina","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei Q","year":"2023","unstructured":"Wei Q, Wang H, Zhao J, et al.. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis. Front Pharmacol. 2023, 14:1237234. 10.3389\/fphar.2023.1237234","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041420","article-title":"Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses","volume":"10","author":"Alves C","year":"2020","unstructured":"Alves C, Penedones A, Mendes D, Batel-Marques F. Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. BMJ Open. 2020, 10:e041420. 10.1136\/bmjopen-2020-041420","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie W","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019, 78:1048-54. 10.1136\/annrheumdis-2018-214846","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267749","article-title":"Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study","volume":"14","author":"Yoshida S","year":"2023","unstructured":"Yoshida S, Miyata M, Suzuki E, et al.. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study. Front Immunol. 2023, 14:1267749. 10.3389\/fimmu.2023.1267749","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin CM","year":"2020","unstructured":"Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020, 31:100-4. 10.31138\/mjr.31.1.100","journal-title":"Mediterr J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky AM","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022, 14:1001. 10.3390\/pharmaceutics14051001","journal-title":"Pharmaceutics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini J","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, et al.. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020, 10:1002. 10.3390\/biom10071002","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JCN.0000000000000873","article-title":"Symptoms of acute myocardial infarction as described in calls to Tele-nurses and in questionnaires: a mixed-methods study","volume":"38","author":"\u00c4ngerud KH","year":"2023","unstructured":"\u00c4ngerud KH, Ericsson M, Br\u00e4nnstr\u00f6m M, Sederholm Lawesson S, Str\u00f6mberg A, Thyl\u00e9n I. Symptoms of acute myocardial infarction as described in calls to Tele-nurses and in questionnaires: a mixed-methods study. J Cardiovasc Nurs. 2023, 38:150-7. 10.1097\/JCN.0000000000000873","journal-title":"J Cardiovasc Nurs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043169","article-title":"A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology","volume":"24","author":"Pastori D","year":"2023","unstructured":"Pastori D, Cormaci VM, Marucci S, et al.. A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci. 2023, 24:3169. 10.3390\/ijms24043169","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2018.04.003","article-title":"Diagnosis of deep venous thrombosis and pulmonary embolism: new imaging tools and modalities","volume":"39","author":"Rahaghi FN","year":"2018","unstructured":"Rahaghi FN, Minhas JK, Heresi GA. Diagnosis of deep venous thrombosis and pulmonary embolism: new imaging tools and modalities. Clin Chest Med. 2018, 39:493-504. 10.1016\/j.ccm.2018.04.003","journal-title":"Clin Chest Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002783","article-title":"Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb","volume":"19","author":"Broderick C","year":"2021","unstructured":"Broderick C, Watson L, Armon MP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev. 2021, 19:002783. 10.1002\/14651858.CD002783","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors","volume":"46","author":"Yang V","year":"2023","unstructured":"Yang V, Kragstrup TW, McMaster C, et al.. Managing cardiovascular and cancer risk associated with JAK inhibitors. Drug Saf. 2023, 46:1049-71. 10.1007\/s40264-023-01333-0","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271780-evaluating-the-usage-of-janus-kinase-inhibitors-in-rheumatology-and-its-impact-on-cardiovascular-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T18:35:53Z","timestamp":1722191753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271780-evaluating-the-usage-of-janus-kinase-inhibitors-in-rheumatology-and-its-impact-on-cardiovascular-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,28]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.65591","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,28]]}}}